Oxcarbazepine
Obstetric Disorder
University of PittsburghSmall moleculeUnknownActive
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 89/ 100
Competitive context
3 Active assets in the Obstetric Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Misoprostol University of Texas at Austin | Phase 4 | BBB |
Cefazolin Michael Stitely | Phase 4 | BBB |
Prostaglandin E1 Hillel Yaffe Medical Center | Phase 2/3 | B |
Aspirin Instituto Nacional de Investigacao em Saude, Angola | Phase 1/2 | CC |
Lamotrigine University of Pittsburgh | Unknown | D |
Dinoprostone Centre Hospitalier Departemental Vendee | N/A | D |
Same molecule, other indications
Oxcarbazepine is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →